

Electronic Acknowledgement Receipt

EFS ID:	5659341
Application Number:	10544093
International Application Number:	
Confirmation Number:	6443
Title of Invention:	ACTIVE IMMUNIZATION TO GENERATE ANTIBODIES TO SOLUBLE A-BETA
First Named Inventor/Applicant Name:	Ted Yednock
Customer Number:	20350
Filer:	Rosemarie L. Celli/Diane Wiggird
Filer Authorized By:	Rosemarie L. Celli
Attorney Docket Number:	15270J-009820US
Receipt Date:	07-JUL-2009
Filing Date:	03-MAR-2006
Time Stamp:	19:04:44
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	5064
Deposit Account	201430
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		15270C-009820US_SID5_2009-07-07.PDF	807884 66b1ace0f70406f55ae12b8dcb6d7139943362d4	yes	15
Multipart Description/PDF files in .zip description					
	Document Description		Start		End
	Transmittal Letter		1		8
	Information Disclosure Statement (IDS) Filed (SB/08)		9		15
Warnings:					
Information:					
2	Foreign Reference	1102-EP1690547A1.pdf	705480 10097778d6aa3924baf1490751a0971ae70258f64d4	no	60
Warnings:					
Information:					
3	Foreign Reference	1135-WO08131298_repud.pdf	208262 081100888a40a990a738861c12c0a304785f057d6d8	no	4
Warnings:					
Information:					
4	Foreign Reference	1107-WO2008131298.pdf	4159538 3d7f6ae93a75348cc9db7baf006303de0bdc5d65b	no	87
Warnings:					
Information:					
5	Foreign Reference	1133-WO06042158A2A3.pdf	3541579 a20abae0b12f135f0c18c450412ce0bd116926e4	no	64
Warnings:					
Information:					
6	Foreign Reference	1146-WO05035753.pdf	4814834 0648131518f6a7da3ebc836e434dc201318f07ada	no	143
Warnings:					
Information:					

7	Foreign Reference	1152-WO0178777.pdf	1083689 c7fd461ad486c97d9027b55c7d8bca8c5f618d9	no	19
Warnings:					
Information:					
8	Foreign Reference	1173-WO9718855.pdf	3480595 37d11a3dc9919d6a8a70f51113d749607a0d8	no	82
Warnings:					
Information:					
9	Foreign Reference	1151-WO9639834.pdf	2865055 5d28c5b69130625d47bae2442b1a210a5e17f0f	no	63
Warnings:					
Information:					
10	Foreign Reference	1174-WO9014840.pdf	3708654 882ec7a1c2839fbc2c5d4336a897d3d8f8ad74	no	97
Warnings:					
Information:					
11	Foreign Reference	1145-WO87002671.pdf	4461100 47becb6d6c959643070b5115c5888e1bc0d6d8f	no	129
Warnings:					
Information:					
12	NPL Documents	1120-ArmourRecombinantHumanIgG_1999.pdf	991519 a1f6472780177cacd82d8ba183b95a17b87895c2	no	12
Warnings:					
Information:					
13	NPL Documents	1117-Remington17thparenteral.pdf	311786 ab2ab8018c81ca9e5a925595b0d0dd52f55235	no	5
Warnings:					
Information:					
14	NPL Documents	1138-Brinkman_SpliceVariants_2004.pdf	813327 d27a10b655ec505363d8f0146d18d9c8855c68	no	11
Warnings:					
Information:					
15	NPL Documents	1110-Chen_SelectionandAnalysis_1999.pdf	1334255 5628c57070111d9d5c3eecc8ae8041718c3134	no	17
Warnings:					
Information:					

16	NPL Documents	1142- Choi_AGenericIntron_1991.pdf	457474 9bc1345464ba410491dc483481dc66cbb 14c41	no	5
Warnings:					
Information:					
17	NPL Documents	1132- Corcoran_Overexpression.pdf	992540 a952625a5f55da9f1ba7f6e19f1d6bde77 d6c07c	no	10
Warnings:					
Information:					
18	NPL Documents	1144- database_Nucleotide_2005.pdf	75969 9d888bdc177ba1b4d424d4596a603d2553bc 5d5d8	no	2
Warnings:					
Information:					
19	NPL Documents	1137_ExtendedEPOSearch_058 124366_12-18-08.pdf	612214 c51705e8b15b5b2b3d6dc8d02e98c951ac 8c786	no	13
Warnings:					
Information:					
20	NPL Documents	1136- SupplEPSearch_047762520_09- 23-08.pdf	247188 139693939698a548b26186e03315a093e 9300	no	6
Warnings:					
Information:					
21	NPL Documents	1130- EPcommunicationfor04720353 _4_12-8-00.pdf	646846 6b2426e7758b95d87159336c5dc92ba7cf 80c	no	6
Warnings:					
Information:					
22	NPL Documents	1134- EPOExam_080114093_11_20_0 8.pdf	512921 3d8c760a62df1b76e5c262dc3694242f8f1b 795c	no	14
Warnings:					
Information:					
23	NPL Documents	1150- InpadocFileof_EP0613007.pdf	75361 2184babdc0d2c97a0bb1d8bc6c6af5c315d 23155	no	4
Warnings:					
Information:					
24	NPL Documents	1163-Genbank_AAA69734.pdf	87872 931378d127c0edf9bc4959ba097796311bc 5d8d5	no	2
Warnings:					
Information:					

25	NPL Documents	1164-Genbank_BAC01733.pdf	120340 70913c4457118bacd961571a3dffc1c173f4cc4	no	3
Warnings:					
Information:					
26	NPL Documents	1118-Hazareh_EffectiveFunctionActivities.pdf	828888 4d97d1f5dbd086c45348b276d53db10ca49164	no	8
Warnings:					
Information:					
27	NPL Documents	1127-Janeway_Immunobio_1997.pdf	913722 d87e12098ed2009b7116c14d78ec0fcb7807e1	no	5
Warnings:					
Information:					
28	NPL Documents	1121-Mann_Atypica_Amyloid1996.pdf	948363 94cac14286d7d8661e12367910792b0bce1803e	no	8
Warnings:					
Information:					
29	NPL Documents	1122-Mann_Predomdepo1996.pdf	1918572 5c1d67a3c9e80d813ade0fe1ab86eefbf3e427c2	no	10
Warnings:					
Information:					
30	NPL Documents	1157-Mavragani_ACaseofReversible.pdf	236596 6577eae0565e16dbd0174e3ce91a8c2e88019	no	2
Warnings:					
Information:					
31	NPL Documents	1139-Myers_targetingImmune_2002.pdf	1198330 048bd24d89c72ed7b7a05cd079ac99277bce4cc	no	13
Warnings:					
Information:					
32	NPL Documents	1167-Padlan_StrucofAntibody-AntigenComplex_1989.pdf	854883 2ee1b1e1d85f945d4b0e4db011cd9f9ed55c624	no	5
Warnings:					
Information:					
33	NPL Documents	1171-Pangalos_DiseaseModifying_2005.pdf	482563 9d8e1c6f1eca425ae9f354298daef35e702d9dc	no	6
Warnings:					
Information:					

34	NPL Documents	1108-Pascalis_GraftingAbbreviatedComplementarity_2002.pdf	934189 8b95c1a6e88019d7149ebc3aed91fa27b9a0866	no	9
Warnings:					
Information:					
35	NPL Documents	1158-WrittenOpin_PCTUS0880370.pdf	461999 464972b49c1c944b8f8b3bc702e0b11324411d09f	no	8
Warnings:					
Information:					
36	NPL Documents	1159-PCTUS0880370_searchreport.pdf	143285 ee47004b7b18f496a5ae2f82ccdc0c8a88017a0efcc	no	3
Warnings:					
Information:					
37	NPL Documents	1172-Prada_Antibody-Mediated_2007.pdf	847611 d3dc3d005be18ae8836f53b671c23d1c576af	no	8
Warnings:					
Information:					
38	NPL Documents	1149-Qu_AB42GeneVaccine_AB42Depo_2007.pdf	2077916 afcc66820321a113184cf020903157c2018249705c	no	10
Warnings:					
Information:					
39	NPL Documents	1141-Robbins_TheIntronic_1997.pdf	506425 b2773c70568f8b9c35c355846d18ffed4b13bf	no	6
Warnings:					
Information:					
40	NPL Documents	1123-Schmidt_Monoclonal_Antibod1997.pdf	871874 59e97c8ac189266e681bdf0a2663daf639a3ade	no	12
Warnings:					
Information:					
41	NPL Documents	1165-Schroeder_Preferential_1990.pdf	587011 012d518d99d1c0caaf9e7d846c0f8ba77816d89	no	5
Warnings:					
Information:					
42	NPL Documents	1140-Seabrook_SpeciesSpecific_2004.pdf	860603 af7ca7ab01bcb31281bb46d727efc61a6b011169	no	11
Warnings:					
Information:					

43	NPL Documents	1119-Sherpherd_APracticalApp_2000.pdf	528527 162ed8bedaff9c7af1261075826b51c4c0173407	no	8
Warnings:					
Information:					
44	NPL Documents	1104-Sidhu_PageDisplayinPharmacutical_2000.pdf	746671 7afdb127a29d4b4258a2ab189f61e09b79296a0f900	no	7
Warnings:					
Information:					
45	NPL Documents	1105-Smith_PhageDisplay_1997.pdf	2280879 f7bfe0e951a4f0124915cb1f5abdcfbcb207395a72c	no	20
Warnings:					
Information:					
46	NPL Documents	1128-Studnicka_abstract.pdf	101480 ed78095028d8547822c7146a0117cac2c664473b	no	2
Warnings:					
Information:					
47	NPL Documents	1124-Tamaoka_Antibodto_amyloid1996.pdf	862086 7a2ee95d481002a6a117b4c20cd93a7a7ed951b	no	10
Warnings:					
Information:					
48	NPL Documents	1162-Trang_1990.pdf	526651 a4292ab1c37f14e01c6ca369a028f5c0885c19	no	6
Warnings:					
Information:					
49	NPL Documents	1112-09316387_FinalOfficeAction_09-10-07.pdf	555162 a540d5306a335d4737cd8f150249407b6be308c	no	15
Warnings:					
Information:					
50	NPL Documents	1113-09316387_ResptOaFile_d_12-20-2005.pdf	525300 98651a354a72e9959295038b3ed76bce07d9f	no	16
Warnings:					
Information:					
51	NPL Documents	1114-US09316387_DecofSolomonHrncicWall_03-06-2006.pdf	340260 28ced704995f9a134c3b0e123f8e11b021d5eac	no	7
Warnings:					
Information:					

52	NPL Documents	1115- US09316387_OAmailed_06-20-2005.pdf	1210599 6957e8f1881cd21b4d5ee7aee293181f3b2549730a	no	29
Warnings:					
Information:					
53	NPL Documents	1109- Vajdos_ComprehensiveFunctionalMaps_2002.pdf	1145757 880b74ac30580b4d81b3a6d755db74bf07a6527	no	14
Warnings:					
Information:					
54	NPL Documents	1143- Ward_SpontaneousDeletions_1991.pdf	470487 22352167911f6cc35f812bf31c15619ee5942401ba0	no	6
Warnings:					
Information:					
55	NPL Documents	1161-Antibody.pdf	323933 7bed199a6f9cc462aa661790fa66dc2e78a4b0	no	15
Warnings:					
Information:					
56	NPL Documents	1106- Wilson_PhageDisplayApplications_1998.pdf	1810382 56de175c1ef48b0c6d9b8a810bdebf993103c18	no	17
Warnings:					
Information:					
57	NPL Documents	1111- Wu_HumanizationofMurine_1999.pdf	1090938 41781624783d5e3ba18d18d3862509887097aee0b	no	12
Warnings:					
Information:					
58	NPL Documents	1125- Yanagisawa_Amyloid_BETA1997.pdf	468603 2126584601a827e6f4d7cdc7d729f37c83cc55c5	no	4
Warnings:					
Information:					
59	NPL Documents	1126-Yang_MonoAntibod1994.pdf	564236 68a516cf36d7316c99f947b6ab59b7bf117180fb	no	4
Warnings:					
Information:					
60	Fee Worksheet (PTO-875)	fee-info.pdf	30716 a28b3399727cc55d65d899184f4d2ee55e5dbf	no	2
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.